At City of Hope, prostate cancer clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes. Our patients have access to a wide variety of clinical trials, including innovative chemotherapy, targeted therapies and hormone therapies with fewer side effects, as well as advanced surgical techniques, radiation approaches and prevention strategies.
Prostate Cancer Research Projects
City of Hope is a leader in prostate cancer research, with the following among the projects currently being investigated:
Using focused ultrasound to heat up and destroy prostate cancer
Identifying and incorporating biomarkers for better detection of prostate cancer development, progression and recurrence, possibly bypassing the need for biopsies to make a diagnosis
Using neural stem cells to target and deliver cancer-fighting drugs to prostate cancer cells throughout the body
New imaging methods to detect microscopic disease outside the prostate
Using reengineered immune cells to target and attack prostate cancer throughout the body
Examining the benefits of surgery for patients with metastatic prostate cancer
Use of natural therapies, such as white mushroom powder, to help prevent prostate cancer recurrence
Long-term follow-up with prostate cancer survivors to detect and manage long-term effects and improve their quality of life
What Are the Ongoing Clinical Trials for Prostate Cancer?
Compassionate patient care means a commitment to research. Not only do our clinical trials give current patients access to promising, leading-edge therapies — they also improve overall care for future patients worldwide.
PSCA-Targeted CAR T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer
NCT03873805: Principal investigator Tanya Dorff, M.D., is recruiting for this Phase 1 trial studying the side effects and best dose of prostate-stem-cell-antigen-CAR T cells in treating patients with PSCA+ castration-resistant prostate cancer that has spread to other places in the body (metastatic).
Patient Enrollment Qualifications
Men 18 years of age or older
Diagnosed with metastatic castration-resistant prostate cancer
ADT, Abiraterone and Ralazoparib in Metastatic Hormone-Sensitive Prostate Cancer, Enriched for a Diverse Population
NCT04734730: Principal investigator Tanya Dorff, M.D., is recruiting for this Phase 2 trial on increasing the efficacy of first-line therapy for men with metastatic hormone-sensitive prostate cancer by adding the PARP inhibitor talazoparib to standard therapy with androgen deprivation therapy (ADT) and abiraterone acetate (abiraterone).
NCT03361735: Principal investigator Savita Dandapani, M.D., Ph.D., is recruiting for this Phase 2 trial studying radium Ra 223 dichloride, hormone therapy (using leuprolide acetate or goserelin acetate) and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body.
White Button Mushroom Trial for Biochemical Recurrence and Active Surveillance
NCT04519879: Principal investigator Clayton S. Lau, M.D., is recruiting for this Phase 2 trial studying how well a white button mushroom supplement works in reducing prostate-specific antigen levels in patients with recurrent or therapy-naïve prostate cancer. A white button mushroom supplement may affect PSA levels, various parameters of the immune system and levels of hormones that can play a role in prostate cancer growth.
SIMCAP (Surgery in Metastatic Carcinoma of Prostate)
NCT03456843: Principal investigator Bertram Yuh, M.D., M.I.S.M., M.S.H.C.P.M., is recruiting for this randomized Phase 2 trial on how well surgical removal of the prostate and antiandrogen therapy (with or without docetaxel) work in treating men with newly diagnosed metastatic prostate cancer.
NCT05204147: IRB#20449 Principal investigator Jeffrey Y. Wong, M.D., is recruiting for this Phase 1 study testing the safety of actinium Ac 225-DOTA-anti-carcinoembryonic antigen monoclonal antibody M5A and its side effects and best dosage for patients with advanced CEA-expressing cancer.
NCT03361735: IRB#17085 Principal investigator Savita Dandapani, M.D., Ph.D., is recruiting for this Phase 2 trial studying radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body.
NCT04644770: IRB#20532 Principal investigator Jeffrey Y. Wong, M.D., is recruiting for this study to determine the recommended Phase 2 doses of JNJ-69086420 in Part 1 (Dose Escalation) and determine safety and preliminary signs of clinical activity at Part 2 (Dose Expansion).
Patient Enrollment Qualifications
Men 18 years of age or older
Diagnosed with metastatic castration-resistant prostate cancer and adenocarcinoma of the prostate
